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T he expanded use of cardiac rhythm management devices (CRMDs) during the last 20 years has sub-
stantially improved the quality of life of 
our patients and in many cases has been 
convincingly proved to improve long-term 
prognosis and survival rates.1,2 However, 
we have to be aware that CRMDs are a 
paradigm of a demanding, high-cost ther-
apy that should be used in carefully select-
ed patients by well trained physicians in 
appropriately selected centers. The most 
important justification of this fact is the 
profound impact that complications of 
CRMDs can have on our patients’ health 
and on health care systems.3 Although a 
plethora of studies have been published 
on the medical aspects of CRMD-related 
complications, there is a lack of data re-
garding their financial impact. In this con-
text, the article by Fanourgiakis et al4 in 
this issue of the HJC provides valuable in-
formation that needs to be taken into con-
sideration by health providers and health 
payers.
Prolongation of hospitalization is the 
most common index of increased health 
costs and it has a profound financial ef-
fect. In the study by Fanourgiakis et al, the 
average prolongation of the hospital stay 
for patients presenting with a complica-
tion was 7 days, ranging from 1 to 35 days. 
Based on 2012 Greek National Health 
System charges, the overall additional di-
rect cost per complication, including hos-
pitalization cost, medication cost, labora-
tory and imaging diagnostic examinations, 
was €17,411. The important contribution 
of this study is that, for the first time in 
Greece, an evidence-based approach has 
evaluated the direct cost of CDRM com-
plications.
The most important limitation of this 
study is that the rate of complications was 
very low, significantly lower than that re-
ported by other studies. The low incidence 
of complications in this observational 
study of cardiac pacing can be attribut-
ed either to selection bias or to the fact 
that the authors’ center is a referral cen-
ter, where the experience and quality of 
service may be higher than average. Giv-
en the importance of this economic analy-
sis, which is augmented by the unfavorable 
effects of the economic crisis on health 
costs, we need to expand the value of this 
work by focusing on the cost of complica-
tions as a factor that influences the over-
all cost of each CRMD procedure in every 
center on a countrywide basis.
In order to do so, we have to establish 
a countrywide registry that would include 
every CRMD implantation and prospec-
tively follow the patients for at least one 
year in order to record complications. By 
doing so, based on the data on the eco-
nomic costs of complications presented in 
the study by Fanourgiakis et al, we shall be 
able to reliably calculate the overall cost 
of treatment with a CRMD.
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Why is knowledge of financial implications important for 
our patients?
The apparent benefits of following such a strategy 
are the validation of the quality of practice and the 
improvement of management of health costs in this 
section of public health. But most importantly, such 
a strategy may also facilitate the adaptation of ad-
vances in cardiac pacing. For example, we do not re-
ally know the true additional cost of leadless pacing, 
because we do not have reliable data to address the 
additional costs of complications related to transve-
nous pacing, taking into account the cost of common 
complications such as pocket infection and lead dis-
lodgment.
Hence, trying to accurately calculate the inci-
dence and cost of CRMD-related complications is 
not only of economic importance. Most importantly, 
it is a valuable first step towards improving care for 
our patients using recent advances in the field of pac-
ing that, despite a higher front cost, may be cost-ef-
fective because of the lower costs of complications. 
Meanwhile, these data should be used to improve the 
quality of our practice, focusing on the prevention of 
common complications that have an enormous effect 
on both patients and health payers.
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